Department of Infectious Diseases, Genentech Inc., South San Francisco, California, USA.
Department of Discovery Chemistry, Genentech Inc., South San Francisco, California, USA.
mBio. 2024 Oct 16;15(10):e0089724. doi: 10.1128/mbio.00897-24. Epub 2024 Aug 29.
Guanine nucleotides are required for growth and viability of cells due to their structural role in DNA and RNA, and their regulatory roles in translation, signal transduction, and cell division. The natural antibiotic mycophenolic acid (MPA) targets the rate-limiting step in guanine nucleotide biosynthesis executed by inosine-5´-monophosphate dehydrogenase (IMPDH). MPA is used clinically as an immunosuppressant, but whether inhibition of bacterial IMPDH (GuaB) is a valid antibacterial strategy is controversial. Here, we describe the discovery of extremely potent small molecule GuaB inhibitors (GuaBi) specific to pathogenic bacteria with a low frequency of on-target spontaneous resistance and bactericidal efficacy against mouse models of infection. The spectrum of GuaBi activity includes multidrug-resistant pathogens that are a critical priority of new antibiotic development. Co-crystal structures of , and GuaB proteins bound to inhibitors show comparable binding modes of GuaBi across species and identifies key binding site residues that are predictive of whole-cell activity across both Gram-positive and Gram-negative clades of Bacteria. The clear efficacy of these small molecule GuaB inhibitors in a model of infection validates GuaB as an essential antibiotic target.
The emergence of multidrug-resistant bacteria worldwide has renewed interest in discovering antibiotics with novel mechanism of action. For the first time ever, we demonstrate that pharmacological inhibition of guanine biosynthesis is bactericidal in a mouse model of infection. Structural analyses of novel inhibitors explain differences in biochemical and whole-cell activity across bacterial clades and underscore why this discovery may have broad translational impact on treatment of the most recalcitrant bacterial infections.
由于鸟嘌呤核苷酸在 DNA 和 RNA 中的结构作用,以及在翻译、信号转导和细胞分裂中的调节作用,它们是细胞生长和存活所必需的。天然抗生素霉酚酸(MPA)针对的是肌苷-5′-单磷酸脱氢酶(IMPDH)执行的鸟嘌呤核苷酸生物合成的限速步骤。MPA临床上用作免疫抑制剂,但抑制细菌 IMPDH(GuaB)是否是一种有效的抗菌策略存在争议。在这里,我们描述了极其有效的小分子 GuaB 抑制剂(GuaBi)的发现,这些抑制剂针对具有低自发耐药率的致病菌,对感染的小鼠模型具有杀菌功效。GuaBi 活性的范围包括对新抗生素开发具有关键优先地位的多药耐药病原体。与抑制剂结合的 GuaB 蛋白的共晶结构显示了 GuaBi 在物种间的可比结合模式,并确定了关键结合位点残基,这些残基可预测整个细胞在革兰氏阳性和革兰氏阴性细菌群中的活性。这些小分子 GuaB 抑制剂在感染模型中的明确疗效验证了 GuaB 作为一种必需的抗生素靶标。
世界各地多药耐药菌的出现重新激发了人们对发现具有新型作用机制的抗生素的兴趣。我们首次证明,在感染的小鼠模型中,鸟嘌呤生物合成的药理学抑制具有杀菌作用。对新型抑制剂的结构分析解释了跨细菌群的生化和全细胞活性的差异,并强调了这一发现为何可能对治疗最顽固的细菌感染具有广泛的转化影响。